Clinical Trial Update: ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial [Phase 2]

View source ↗

Summary

The document summarizes Bayer's completed Phase IIa dose-escalation proof-of-principle trial of ODiXahip for the prevention of venous thromboembolism.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Deep Vein Thrombosis
• Pulmonary Embolism
• Venous Thromboembolism

Drugs mentioned

• ODiXahip

Snippet

Sponsor: Bayer | Conditions: Thromboembolism, Prevention | Phase 2 | Status: COMPLETED